Law360, New York (November 09, 2009) -- Allergan Inc. continues to pounce on rival drugmakers' attempts to market generic versions of Combigan, most recently accusing Alcon Inc. of infringing three patents for the glaucoma treatment.
The complaint, lodged Friday in the U.S. District Court for the Eastern District of Texas, asserts three patents in response to Alcon’s bid for regulatory approval of a knock-off version...
